Clinical Trial Update: Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors [EARLY_Phase 1]

View source ↗

Summary

This document reports on the Phase 1 imaging study of the PET radiotracer [18F]3F-PHPG in patients with neuroendocrine tumors. It focuses on the radiotracer's i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• [18F]3F-PHPG (3F-PHPG radiotracer)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Neuroendocrine Tumors | EARLY_Phase 1 | Status: COMPLETED